Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide for AF Recurrence After Catheter Ablation in Obese Patients
NCT07715929Phase 4Not yet recruiting
- Sponsor
- Henan Purui Pharmaceutical
- Start
- Sep 2026
- Primary completion
- Sep 2029
01
Overview
A Phase 4 trial of tirzepatide in Atrial fibrillation (AFib), obesity, sponsored by Henan Purui Pharmaceutical. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
03
Conditions
Atrial fibrillation (AFib)obesity
Beyond the preview
Go deeper on NCT07715929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07715929.